Navigation Links
SPOC, Inc. announces completion of $300,000 follow-on investment by Connecticut Innovations
Date:10/31/2007

HOBOKEN, N.J. Stevens Proof of Concept Inc. (SPOC) of Stamford, Conn., a Technogenesis Company incubated at Stevens Institute of Technology, and Connecticut Innovations (CI), the states quasi-public authority responsible for technology investing and innovation development, have announced that CI has completed a follow-on pre-Series A investment of $300,000 in SPOC. CI made this investment through its Eli Whitney Fund. Earlier this year, CI invested in SPOC through its Connecticut BioSeed Fund.

SPOC was formed in July 2005 at Stevens Institute of Technology, Hoboken, New Jersey, by its University Research and Enterprise Development office along with Dr. Norman Marcus, a leader in pain management, and three Stevens undergraduate students in biomedical engineering. SPOC has developed a proprietary point-of-care medical diagnostic system, consisting of a medical device and methodology that pinpoint the specific myofascial (muscle) trigger points causing pain. The patent pending device is the first use of electroneural stimulation for diagnostic purposes. SPOCs diagnostic system will benefit patients by helping to eliminate treatments that prove to be ineffective, such as surgical procedures, and by allowing physicians to locate more effectively and to treat muscles that generate pain.

Since approximately 100 million people in the United States suffer from chronic pain and approximately 80 percent of Americans suffer from some form of pain in their lifetime, the potential market for such a system is enormous.

Vikki Hazelwood, chief executive officer of SPOC, commented, We are pleased to have had such solid and active support from our investors CI and Stevens. CIs follow-on financing will ensure that we maintain our stride as we continue to develop SPOC Inc. in Stamford and position it well for our Series A investment.

Dr. Helena Wisniewski, vice president of University Research and Enterprise Development at Stevens Institute of Technology added, We appreciate CIs commitment to SPOC. The additional funding from CI provides a confirmation of SPOCs commercial value. CIs business guidance together with its funding has contributed significantly to SPOCs rapid development, and we feel that working together we can reach SPOCs true market potential.

We have been extremely encouraged by the ability of the team at SPOC to achieve its technical and business milestones, said Peter Longo, president and executive director of CI. Progress at the company has been faster and better than anticipated. Consequently, we wanted to help the company maintain its strong momentum and have supported it with this follow-on funding. Longo added, We look forward to providing further investment assistance to SPOC in early 2008, when it will be seeking a Series A round of funding.


'/>"/>

Contact: Patrick A. Berzinski
pberzins@stevens.edu
201-216-5687
Stevens Institute of Technology
Source:Eurekalert

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... ... the first technology to directly address the resolution to globally reduce the harmful ... a patented compound of FDA and TTB approved ingredients that when infused into ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, Inc., the developer of ... Siemens Healthineers annual customer education symposium, a world-class learning conference that offers educational ... 27 - 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , ...
(Date:3/28/2017)... ... March 29, 2017 , ... The Thyroid Secret is a ... FASCP. The program was recently launched on March 1, and Dr. Wentz discussed ... , Dr. Izabella Wentz is a licensed pharmacist and a foremost thyroid ...
(Date:3/28/2017)... Seattle, WA (PRWEB) , ... March 28, 2017 ... ... reach a 22% share of all holidays (IBT World Travel Trends Report). As ... physically challenging, include a range in temperatures, and prolonged sun exposure. In response, ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... advancing the science and clinical practice of radiosurgery, announced today the publication ... multi-institutional, observational registry established to standardize data collection from patients treated with ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... 2017 The global emerging cancer diagnostics market ... from 2016 to 2023 and reach a figure of ... is a chronic disease and is affecting a huge ... market. This report is focused on emerging cancer diagnostics ... is propelled due to factors such as: increasing number ...
(Date:3/28/2017)... 2017  Medeon Biodesign, Inc., a ... to announce that the Company led and successfully ... Inc., a San Jose, CA ... orthopedic extremity applications.  The orthopedic ... due to procedure volume growth, lifestyle influences and ...
(Date:3/28/2017)... -- "US Cancer Generics Market Outlook 2022" report gives ... analysis related to the emergence and integration of ... US. The report analyzes various clinical and non-clinical ... drugs in recent years. The introduction of generics ... for various stake holders involved US cancer drug ...
Breaking Medicine Technology: